SHZ:002020
Zhejiang Jingxin Pharmaceutical Co., Ltd. · SHZ · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 12:28 UTC
Last close
n/aCNY
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
13.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
13.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
18.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
14.2%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.05Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
2.8%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Growth is the furthest below its sector's middle: 0.37 against 0.47 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.22x
Its own average over 10 years, 3.34B.
- Profit1.41x
Its own average over 10 years, 537.1M.
- Free cash flow2.13x
Its own average over 10 years, 271.7M.
- Debt1.19x
Its own average over 10 years, 258.2M.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 2.13 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 118.3 | 132.4 | 105.1 |
| 2018-12-31 | 157.0 | 184.9 | 113.2 |
| 2019-12-31 | 194.4 | 260.5 | 106.3 |
| 2020-12-31 | 173.7 | 326.9 | 103.3 |
| 2021-12-31 | 184.8 | 306.7 | 106.6 |
| 2022-12-31 | 201.5 | 331.5 | 112.3 |
| 2023-12-31 | 213.2 | 309.8 | 112.2 |
| 2024-12-31 | 221.7 | 356.4 | 112.0 |
| 2025-12-31 | 217.0 | 379.5 | 107.6 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Figures behind the shape
Growth
4.5%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate4.5%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Five-year EPS growth rate2.2%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
One-year change in net income6.5%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Returns on capital
13.4%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capital13.4%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity13.0%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets9.3%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
50.1%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin50.1%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin20.8%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin18.6%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin14.2%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
13.4xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earnings13.4x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
Price to book1.7x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA8.6x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio2.5x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.05safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equity0.05
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio1.73
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage213.6x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score4.33
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
2.8%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07
Dividend yield2.8%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Payout ratio37.6%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio2.0x
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.